The B Cell Company

La Jolla Pharmaceutical Company

Two types of autoimmune diseasesTwo types of autoimmune diseases

B cellsB cellsDisease-causing

antibodiesDisease-causing

antibodies

LupusStroke MI DVTXenotransplantation Myasthenia GravisRh Hemolytic Disease

LupusStroke MI DVTXenotransplantation Myasthenia GravisRh Hemolytic Disease

T cellsT cells

Rheumatoid ArthritisDiabetesMultiple SclerosisScleroderma

Rheumatoid ArthritisDiabetesMultiple SclerosisScleroderma

Lupus1,000,000Lupus1,000,000

Market opportunity $4 billionMarket opportunity $4 billion

StrokeHeart attackDeep vein thrombosis500,000

StrokeHeart attackDeep vein thrombosis500,000

Xenotransplantation200,000+

Xenotransplantation200,000+

Rh HemolyticDisease40,000

Rh HemolyticDisease40,000 Myasthenia Gravis

40,000Myasthenia Gravis

40,000

Product pipelineProduct pipeline

LJP 394 - Lupus

LJP 920 - XenotransplantationLJP 993 - Thrombosis

LupusLupus

Antibody-mediated thrombosisAntibody-mediated thrombosis

XenotransplantationXenotransplantation

Contract manufacturingContract manufacturing

LupusLupus

Antibody-mediated thrombosisAntibody-mediated thrombosis

XenotransplantationXenotransplantation

Contract manufacturingContract manufacturing

Current therapy problemsCurrent therapy problems

SteroidsSteroids• Diabetes, hypertension, Diabetes, hypertension,

cataracts, osteoporosis cataracts, osteoporosis

and psychosisand psychosis• Lead to severe infectionsLead to severe infections

ChemotherapyChemotherapy• Weight loss, nausea and sterilityWeight loss, nausea and sterility• Increased risk of malignanciesIncreased risk of malignancies• Lead to severe infectionsLead to severe infections

SteroidsSteroids• Diabetes, hypertension, Diabetes, hypertension,

cataracts, osteoporosis cataracts, osteoporosis

and psychosisand psychosis• Lead to severe infectionsLead to severe infections

ChemotherapyChemotherapy• Weight loss, nausea and sterilityWeight loss, nausea and sterility• Increased risk of malignanciesIncreased risk of malignancies• Lead to severe infectionsLead to severe infections

Daniel J. Wallace, M.D.Cedars-Sinai UCLA

Click Photo to play video

Steroids

Reducing antibody rises prevents flaresReducing antibody rises prevents flares

H. Bootsma et al. The Lancet Feb. 1995H. Bootsma et al. The Lancet Feb. 1995H. Bootsma et al. The Lancet Feb. 1995H. Bootsma et al. The Lancet Feb. 1995

80%80%DiseaseDisease

Patients with flares:Patients

with flares:FlaresFlares

Treatment in response to:Treatment in response to:

Antibody levelAntibody level

10%10%

TimeTime

Antibodylevels

Antibodylevels

Antibody levelAntibody level

FlaresFlares

Steroids

Clinical trial sitesClinical trial sites

ColumbiaEmoryHarvardJohns HopkinsStanfordUCLAUniversity of Chicago

AnimalAnimalOrganOrgan

Xenotransplantation - acute & chronic rejectionXenotransplantation - acute & chronic rejection

The B Cell Company

La Jolla Pharmaceutical Company

Click Escape to end